How and where to watch the Lyrid meteor shower
With the Lyrid meteor shower expected to light up the skies this month, we reveal how to get the best view and what to look for.
This annual celestial display occurs every April when the Earth passes through debris left by comet C/1861 G1 (Thatcher) on its orbit around the Sun – a journey that is thought to take about 416 years. 'It's sort of falling apart as it goes,' said Dr Ed Bloomer, an astronomer at Royal Observatory Greenwich.
As Earth orbits the sun it collides with this debris and the specks of dust burn up in the Earth's atmosphere. That creates a meteor shower, which is seen in the same part of the sky each year. The Lyrids appear to come from near the constellation Lyra, the harp, from which the shower gets its name.
It is thought to be the oldest recorded meteor shower, with sightings documented in China in 687BC.
The Lyrid meteor shower lasts for several days, with Bloomer noting the greatest period of activity is expected to be between 19 and 25 April, although meteors might be visible from early this week.
The shower is best viewed in the northern hemisphere but can be seen in the southern hemisphere where the constellation of Lyra is visible.
Grab a blanket or deck chair, find somewhere dark, and set up your spot. Then glance up.
Bloomer said the best time to view the shower in the UK is about 4-5am. He recommended facing east and then turning about 30 degrees towards the north-east, allowing the meteors to cut across your field of vision.
You can also use star map apps on your phone to help locate the constellation of Lyra.
As Bloomer noted, the Lyrids do not look like fireworks, but rather transient sparks of light – although occasionally larger pieces of debris burn up in the atmosphere resulting in bright, longer-lasting meteors known as fireballs.
'There's no real shortcut to it. You've got to let your eyes adjust to the dark, and you've got to keep at it,' he said. 'The rate might only be 18 per hour.'
Bloomer added that the meteors can come in fits and starts, and a flurry can be followed by several minutes without any. 'And if you blink at the wrong time, you might miss that one,' he said. 'So it's quite a personal experience because you've no time to alert anybody to it.'
Indeed, when it comes to viewing the skies, it seems the most important tool is patience.
'You just have tobliss out a little bit, or be a bit Zen and just look at the sky,' said Bloomer.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
North Wales Chronicle
02-06-2025
- North Wales Chronicle
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
South Wales Guardian
02-06-2025
- South Wales Guardian
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
South Wales Argus
02-06-2025
- South Wales Argus
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
